Literature DB >> 20182788

Incidence rates of exocrine and endocrine pancreatic cancers in the United States.

Jing Zhou1, Lindsey Enewold, Alexander Stojadinovic, Guy T Clifton, John F Potter, George E Peoples, Kangmin Zhu.   

Abstract

Descriptive studies of pancreatic cancer incidence have been sparse particularly in terms of tumor histology and stage. The purpose of this study was to examine the incidence rate trends of exocrine and endocrine pancreatic cancers by demographic and tumor characteristics using data from the Surveillance, Epidemiology, and End Results (SEER) program from 1977 to 2005. During this period, the incidence of exocrine pancreatic cancer generally decreased whereas the incidence of endocrine pancreatic cancer increased. This difference in trends by histology was evident across age, gender, and racial groups. It was also evident among different racial/ethnic groups using data from 1992 to 2005. Variation in trends was observed by stage. The incidence of exocrine cancers declined for all stages except regional. Endocrine cancer incidence increased for all tumor stages, and the increase was most prominent for localized tumors. When exocrine tumors were stratified by tumor subsite, the incidence of cancers in the tail and body regions increased while the incidence in other regions decreased. While better detection and classification of tumors through improved diagnostic procedures may be related to these changing trends, etiologic factors warrant study.

Entities:  

Mesh:

Year:  2010        PMID: 20182788     DOI: 10.1007/s10552-010-9512-y

Source DB:  PubMed          Journal:  Cancer Causes Control        ISSN: 0957-5243            Impact factor:   2.506


  24 in total

1.  Pancreatic cancer incidence trends: evidence from the Surveillance, Epidemiology and End Results (SEER) population-based data.

Authors:  Vanessa L Gordon-Dseagu; Susan S Devesa; Michael Goggins; Rachael Stolzenberg-Solomon
Journal:  Int J Epidemiol       Date:  2018-04-01       Impact factor: 7.196

2.  Noncontrast Radiomics Approach for Predicting Grades of Nonfunctional Pancreatic Neuroendocrine Tumors.

Authors:  Yun Bian; Zengrui Zhao; Hui Jiang; Xu Fang; Jing Li; Kai Cao; Chao Ma; Shiwei Guo; Li Wang; Gang Jin; Jianping Lu; Jun Xu
Journal:  J Magn Reson Imaging       Date:  2020-04-28       Impact factor: 4.813

Review 3.  State-of-the-art Imaging of Pancreatic Neuroendocrine Tumors.

Authors:  Eric P Tamm; Priya Bhosale; Jeffrey H Lee; Eric M Rohren
Journal:  Surg Oncol Clin N Am       Date:  2016-04       Impact factor: 3.495

4.  Incidence and management of postoperative hyperglycemia in patients undergoing insulinoma resection.

Authors:  Pavel Nockel; Amit Tirosh; Mustapha El Lakis; Apostolos Gaitanidis; Roxanne Merkel; Dhaval Patel; Naris Nilubol; Samira M Sadowski; Craig Cochran; Phillip Gorden; Electron Kebebew
Journal:  Endocrine       Date:  2018-06-19       Impact factor: 3.633

5.  Somatostatin and chemokine CXCR4 receptor expression in pancreatic adenocarcinoma relative to pancreatic neuroendocrine tumours.

Authors:  Ylberta Kajtazi; Daniel Kaemmerer; Jörg Sänger; Stefan Schulz; Amelie Lupp
Journal:  J Cancer Res Clin Oncol       Date:  2019-08-26       Impact factor: 4.553

Review 6.  Promising new treatments for pancreatic cancer in the era of targeted and immune therapies.

Authors:  Ahmed Elaileh; Ashish Saharia; Lucy Potter; Flavio Baio; Afnan Ghafel; Maen Abdelrahim; Kirk Heyne
Journal:  Am J Cancer Res       Date:  2019-09-01       Impact factor: 6.166

Review 7.  Pancreatic neuroendocrine tumors: clinical features, diagnosis and medical treatment: advances.

Authors:  Tetsuhide Ito; Hisato Igarashi; Robert T Jensen
Journal:  Best Pract Res Clin Gastroenterol       Date:  2012-12       Impact factor: 3.043

8.  Natural History and Treatment Trends in Pancreatic Cancer Subtypes.

Authors:  Courtney J Pokrzywa; Daniel E Abbott; Kristina A Matkowskyj; Sean M Ronnekleiv-Kelly; Emily R Winslow; Sharon M Weber; Alexander V Fisher
Journal:  J Gastrointest Surg       Date:  2019-01-31       Impact factor: 3.452

9.  Insulinoma Due to Multiple Pancreatic Microadenoma Localized by Multimodal Imaging.

Authors:  Bruna Babic; Xavier Keutgen; Pavel Nockel; Markke Miettinen; Corina Millo; Peter Herscovitch; Dhaval Patel; Naris Nilubol; Craig Cochran; Phillip Gorden; Electron Kebebew
Journal:  J Clin Endocrinol Metab       Date:  2016-08-09       Impact factor: 5.958

10.  Dual inhibition of PI3K and mTOR signaling pathways decreases human pancreatic neuroendocrine tumor metastatic progression.

Authors:  Clarisse Djukom; Laura J Porro; Amy Mrazek; Courtney M Townsend; Mark R Hellmich; Celia Chao
Journal:  Pancreas       Date:  2014-01       Impact factor: 3.327

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.